Agios Pharmaceuticals (AGIO)

Apr 17, 2025, 7:00 AM EDT - 9 days ago

Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025

Mar 5, 2025, 5:52 PM EST - 7 weeks ago

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

Mar 4, 2025, 7:00 AM EST - 7 weeks ago

Agios to Present at Upcoming Investor Conferences

Feb 20, 2025, 7:00 AM EST - 2 months ago

Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

Feb 13, 2025, 1:32 PM EST - 2 months ago

Agios Pharmaceuticals, Inc. (AGIO) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 6:31 AM EST - 2 months ago

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Feb 13, 2025, 6:30 AM EST - 2 months ago

Agios' Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

Feb 6, 2025, 7:00 AM EST - 2 months ago

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Jan 8, 2025, 8:00 AM EST - 3 months ago

Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

BIIB

Jan 3, 2025, 7:00 AM EST - 4 months ago

Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

Dec 18, 2024, 7:00 AM EST - 4 months ago

European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease

Dec 8, 2024, 12:40 PM EST - 4 months ago

Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat

Nov 5, 2024, 9:05 AM EST - 6 months ago

Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition

Oct 31, 2024, 2:16 PM EDT - 6 months ago

Agios Pharmaceuticals, Inc. (AGIO) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 6:30 AM EDT - 6 months ago

Agios Reports Business Highlights and Third Quarter 2024 Financial Results

Oct 17, 2024, 7:00 AM EDT - 6 months ago

Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024

Sep 11, 2024, 7:00 AM EDT - 8 months ago

Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)

Sep 5, 2024, 7:00 AM EDT - 8 months ago

Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024

Aug 27, 2024, 10:18 AM EDT - 8 months ago

Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment

Aug 6, 2024, 5:50 PM EDT - 9 months ago

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

Aug 1, 2024, 1:42 PM EDT - 9 months ago

Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides

Aug 1, 2024, 12:11 PM EDT - 9 months ago

Agios Pharmaceuticals, Inc. (AGIO) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 6:31 AM EDT - 9 months ago

Agios Reports Business Highlights and Second Quarter 2024 Financial Results

Aug 1, 2024, 6:30 AM EDT - 9 months ago

Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused

Jul 18, 2024, 7:00 AM EDT - 10 months ago

Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024

Jun 12, 2024, 7:41 AM EDT - 11 months ago

Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline

Jun 3, 2024, 6:42 AM EDT - 11 months ago

Agios Pharmaceuticals' blood disorder drug succeeds in late-stage study

Jun 3, 2024, 6:30 AM EDT - 11 months ago

Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

May 30, 2024, 4:05 PM EDT - 11 months ago

Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 14, 2024, 10:00 AM EDT - 1 year ago

Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress

May 3, 2024, 7:00 AM EDT - 1 year ago

Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024

May 2, 2024, 4:32 PM EDT - 1 year ago

Agios Pharmaceuticals, Inc. (AGIO) Q1 2024 Earnings Call Transcript

May 2, 2024, 7:00 AM EDT - 1 year ago

Agios Reports Business Highlights and First Quarter 2024 Financial Results

Apr 18, 2024, 7:00 AM EDT - 1 year ago

Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024

Mar 5, 2024, 7:00 AM EST - 1 year ago

Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024

Feb 22, 2024, 7:00 AM EST - 1 year ago

Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024

Feb 15, 2024, 2:08 PM EST - 1 year ago

Agios Pharmaceuticals (AGIO) Q4 2023 Earnings Call Transcript

Feb 15, 2024, 7:00 AM EST - 1 year ago

Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Feb 2, 2024, 7:00 AM EST - 1 year ago

Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024

Jan 8, 2024, 8:00 AM EST - 1 year ago

Agios Is A Gem, But It Will Need Patience (Rating Upgrade)

Jan 8, 2024, 7:00 AM EST - 1 year ago

Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

Jan 5, 2024, 6:40 AM EST - 1 year ago

Agios Pharmaceuticals: Strong Thalassemia Data Makes A Tempting Bull Case

Jan 3, 2024, 6:49 AM EST - 1 year ago

Agios Pharma's stock soars 19.6% on news of positive results in trial of treatment for rare blood disorder

Jan 3, 2024, 6:42 AM EST - 1 year ago

Agios' blood disorder drug meets goals of late-stage study

Jan 3, 2024, 6:30 AM EST - 1 year ago

Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia

Jan 2, 2024, 7:00 AM EST - 1 year ago

Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024

Dec 9, 2023, 7:00 PM EST - 1 year ago

Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition

Nov 20, 2023, 7:00 AM EST - 1 year ago

Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

Nov 2, 2023, 11:34 AM EDT - 1 year ago

Agios Pharmaceuticals (AGIO) Q3 2023 Earnings Call Transcript

Nov 2, 2023, 9:05 AM EDT - 1 year ago

Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition